Search

Your search keyword '"Delforge, Michel"' showing total 762 results
Start Over Author "Delforge, Michel" Publication Year Range Last 10 years
762 results on '"Delforge, Michel"'

1. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Author

Moreau, Philippe, Mateos, María-Victoria, Gonzalez Garcia, Maria Esther, Einsele, Hermann, De Stefano, Valerio, Karlin, Lionel, Lindsey-Hill, Joanne, Besemer, Britta, Vincent, Laure, Kirkpatrick, Suriya, Delforge, Michel, Perrot, Aurore, van de Donk, Niels W. C. J., Pawlyn, Charlotte, Manier, Salomon, Leleu, Xavier, Martinez-Lopez, Joaquin, Ghilotti, Francesca, Diels, Joris, Morano, Raúl, Albrecht, Claire, Strulev, Vadim, Haddad, Imène, Pei, Lixia, Kobos, Rachel, Smit, Jennifer, Slavcev, Mary, Marshall, Alexander, and Weisel, Katja

Published
2023
Full Text
View/download PDF

3. Teclistamab in Relapsed or Refractory Multiple Myeloma

Author

Moreau, Philippe, Garfall, Alfred L, van de Donk, Niels WCJ, Nahi, Hareth, San-Miguel, Jesús F, Oriol, Albert, Nooka, Ajay K, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun XW, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D, Kobos, Rachel, Krishnan, Amrita, and Usmani, Saad Z

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Clinical Research, Vaccine Related, Clinical Trials and Supportive Activities, Biotechnology, Rare Diseases, Hematology, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B-Cell Maturation Antigen, CD3 Complex, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.MethodsIn this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better).ResultsAmong 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).ConclusionsTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).

Published
2022

4. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Author

Moreau, Philippe, Hulin, Cyrille, Perrot, Aurore, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Zweegman, Sonja, Caillon, Hélène, Caillot, Denis, Avet-Loiseau, Hervé, Delforge, Michel, Dejoie, Thomas, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Mohty, Mohamad, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Orsini-Piocelle, Frédérique, Roussel, Murielle, Schiano de Colella, Jean Marc, van de Donk, Niels WCJ, Wuillème, Soraya, Broijl, Annemiek, Touzeau, Cyrille, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Offner, Fritz, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Réda, Hua, Winnie, Wang, Jianping, Tuozzo, Alba, de Boer, Carla, Rowe, Melissa, Vanquickelberghe, Veronique, Carson, Robin, Vermeulen, Jessica, Corre, Jill, and Sonneveld, Pieter

Published
2024
Full Text
View/download PDF

5. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma

Author

Delforge, Michel, Shah, Nina, San F. Miguel, Jesús, Braverman, Julia, Dhanda, Devender S, Shi, Ling, Guo, Shien, Yu, Peiwen, Liao, Weiqin, Campbell, Timothy B, and Munshi, Nikhil C

Subjects
Chronic Pain, Hematology, Pain Research, Behavioral and Social Science, Rare Diseases, Clinical Trials and Supportive Activities, Health Services, Cancer, Clinical Research, Fatigue, Humans, Multiple Myeloma, Pain, Quality of Life, Receptors, Chimeric Antigen
Abstract

Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class exposed, relapsed and refractory multiple myeloma (RRMM) in the phase 2 KarMMa (Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma) trial. We assessed health-related quality of life (HRQoL) among KarMMa patients. The European Organization for Research and Treatment of Cancer Quality of Life C30 Questionnaire and its supplementary 20-item multiple myeloma module, as well as the EuroQol 5-dimension 5-level instrument, were administered at screening, baseline (≤72 hours before or same day as lymphodepletion), day of ide-cel treatment, and after ide-cel treatment. Mean changes from baseline that exceeded the predetermined threshold of minimally important difference were deemed clinically meaningful. The proportions of patients experiencing clinically meaningful changes in HRQoL were assessed using within-patient change thresholds. Time to stable improvement (≥2 consecutive visits with clinically meaningful HRQoL improvements) was analyzed by using the Kaplan-Meier method. A total of 126 (98%) of 128 patients treated with ide-cel were included in the HRQoL analysis. Pretreatment baseline RRMM burden was high and meaningfully worse than that in the age- and sex-weighted general population. Statistically significant and clinically meaningful improvements from baseline were observed by month 1 for pain (-8.9) and disease symptoms (-10.2), and by month 2 for fatigue (-7.2), physical functioning (6.1), cognitive functioning (6.7), and global health status/QoL (8.0). Clinically meaningful improvements in fatigue, pain, and physical functioning were most prominent at months 9, 12, and 18, respectively, and were sustained through 15 to 18 months after ide-cel treatment. For triple-class exposed patients with RRMM with a poor prognosis and few treatment options, a single ide-cel infusion provides early, sustained, statistically significant, and clinically meaningful improvements in HRQoL. This study was registered at Clinicaltrials.gov as #NCT03361748.

Published
2022

6. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

Author

Terpos, Evangelos, Musto, Pellegrino, Engelhardt, Monika, Delforge, Michel, Cook, Gordon, Gay, Francesca, van de Donk, Niels W. C. J., Ntanasis-Stathopoulos, Ioannis, Vangsted, Annette Juul, Driessen, Christoph, Schjesvold, Fredrik, Cerchione, Claudio, Zweegman, Sonja, Hajek, Roman, Moreau, Philippe, Einsele, Hermann, San-Miguel, Jesus, Boccadoro, Mario, Dimopoulos, Meletios A., Sonneveld, Pieter, and Ludwig, Heinz

Published
2023
Full Text
View/download PDF

7. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

Author

Moreau, Philippe, van de Donk, Niels W. C. J., Delforge, Michel, Einsele, Hermann, De Stefano, Valerio, Perrot, Aurore, Besemer, Britta, Pawlyn, Charlotte, Karlin, Lionel, Manier, Salomon, Leleu, Xavier, Weisel, Katja, Ghilotti, Francesca, Diels, Joris, Elsada, Ahmed, Morano, Raul, Strulev, Vadim, Pei, Lixia, Kobos, Rachel, Smit, Jennifer, Slavcev, Mary, and Mateos, Maria-Victoria

Published
2023
Full Text
View/download PDF

8. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

Author

Delforge, Michel, Patel, Krina, Eliason, Laurie, Dhanda, Devender, Shi, Ling, Guo, Shien, Marshall, Thomas S, Arnulf, Bertrand, Cavo, Michele, Nooka, Ajay, Manier, Salomon, Callander, Natalie, Giralt, Sergio, Einsele, Hermann, Ailawadhi, Sikander, Popa McKiver, Mihaela, Cook, Mark, and Rodríguez-Otero, Paula

Published
2024
Full Text
View/download PDF

9. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

Author

Martin, Thomas G., Moreau, Philippe, Usmani, Saad Z., Garfall, Alfred, Mateos, María-Victoria, San-Miguel, Jesús F., Oriol, Albert, Nooka, Ajay K., Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Krishnan, Amrita, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Delforge, Michel, Trancucci, Danielle, Pei, Lixia, Kobos, Rachel, Fastenau, John, Gries, Katharine S., and van de Donk, Niels W.C.J.

Published
2024
Full Text
View/download PDF

10. Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

Author

Plesner, Torben, Harrison, Simon J., Quach, Hang, Lee, Cindy, Bryant, Adam, Vangsted, Annette, Estell, Jane, Delforge, Michel, Offner, Fritz, Twomey, Patrick, Choeurng, Voleak, Li, Junyi, Hendricks, Robert, Ruppert, Shannon M., Sumiyoshi, Teiko, Miller, Karen, Cho, Eunpi, and Schjesvold, Fredrik

Published
2023
Full Text
View/download PDF

11. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.

Author

Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji, Bahlis, Nizar, Hulin, Cyrille, Orlowski, Robert, Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai, Van Rampelbergh, Rian, Uhlar, Clarissa, Wang, Jianping, Kobos, Rachel, Gries, Katharine, Fastenau, John, and Weisel, Katja

Subjects
Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Pain Measurement, Patient Reported Outcome Measures, Quality of Life, Time Factors, Treatment Outcome
Abstract

PURPOSE: To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS: PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs. RESULTS: A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (< 75 and ≥ 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 (P = .0007 v Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score. CONCLUSION: D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.

Published
2021

12. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

Author

Ludwig, Heinz, Terpos, Evangelos, van de Donk, Niels, Mateos, Maria-Victoria, Moreau, Philippe, Dimopoulos, Melitios-Athanasios, Delforge, Michel, Rodriguez-Otero, Paula, San-Miguel, Jesús, Yong, Kwee, Gay, Francesca, Einsele, Hermann, Mina, Roberto, Caers, Jo, Driessen, Christoph, Musto, Pellegrino, Zweegman, Sonja, Engelhardt, Monika, Cook, Gordon, Weisel, Katja, Broijl, Annemiek, Beksac, Meral, Bila, Jelena, Schjesvold, Fredrik, Cavo, Michele, Hajek, Roman, Touzeau, Cyrille, Boccadoro, Mario, and Sonneveld, Pieter

Published
2023
Full Text
View/download PDF

15. Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).

Author

Touzeau, Cyrille, primary, Beksac, Meral, additional, Terpos, Evangelos, additional, Usmani, Saad Zafar, additional, Krishnan, Amrita Y., additional, Nijhof, Inger S., additional, Janowski, Wojciech, additional, Hulin, Cyrille, additional, Grosicki, Sebastian, additional, Delforge, Michel, additional, McAleer, Dana, additional, Nagle, Sarah, additional, Olyslager, Yunsi, additional, Miller, Jonathan, additional, Craig, Zoe, additional, Khan, Josephine, additional, Kampfenkel, Tobias, additional, Manier, Salomon, additional, and van de Donk, Niels W.C.J., additional

Published
2024
Full Text
View/download PDF

17. Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

Author

Rodriguez-Otero, Paula, primary, Ailawadhi, Sikander, additional, Arnulf, Bertrand, additional, Patel, Krina, additional, Cavo, Michele, additional, Nooka, Ajay K, additional, Manier, Salomon, additional, Callander, Natalie, additional, Costa, Luciano J, additional, Vij, Ravi, additional, Bahlis, Nizar J, additional, Moreau, Philippe, additional, Solomon, Scott R, additional, Delforge, Michel, additional, Berdeja, Jesus, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Favre-Kontula, Linda, additional, Wu, Fan, additional, Piasecki, Julia, additional, Cook, Mark, additional, and Giralt, Sergio, additional

Published
2024
Full Text
View/download PDF

18. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Author

Mateos, Maria-Victoria, Weisel, Katja, De Stefano, Valerio, Goldschmidt, Hartmut, Delforge, Michel, Mohty, Mohamad, Cavo, Michele, Vij, Ravi, Lindsey-Hill, Joanne, Dytfeld, Dominik, Angelucci, Emanuele, Perrot, Aurore, Benjamin, Reuben, van de Donk, Niels W. C. J., Ocio, Enrique M., Scheid, Christof, Gay, Francesca, Roeloffzen, Wilfried, Rodriguez-Otero, Paula, Broijl, Annemiek, Potamianou, Anna, Sakabedoyan, Caline, Semerjian, Maria, Keim, Sofia, Strulev, Vadim, Schecter, Jordan M., Vogel, Martin, Wapenaar, Robert, Nesheiwat, Tonia, San-Miguel, Jesus, Sonneveld, Pieter, Einsele, Hermann, and Moreau, Philippe

Published
2022
Full Text
View/download PDF

20. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

21. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, Heinz, Sonneveld, Pieter, Facon, Thierry, San-Miguel, Jesus, Avet-Loiseau, Hervé, Mohty, Mohamad, Mateos, Maria-Victoria, Moreau, Philippe, Cavo, Michele, Pawlyn, Charlotte, Zweegman, Sonja, Engelhardt, Monika, Driessen, Christoph, Cook, Gordon, Dimopoulos, Melitios A, Gay, Francesca, Einsele, Hermann, Delforge, Michel, Caers, Jo, Weisel, Katja, Jackson, Graham, Garderet, Laurent, van de Donk, Niels, Leleu, Xavier, Goldschmidt, Hartmut, Beksac, Meral, Nijhof, Inger, Schreder, Martin, Abildgaard, Niels, Hajek, Roman, Zojer, Niklas, Kastritis, Efstathios, Broijl, Annemiek, Schjesvold, Fredrik, Boccadoro, Mario, and Terpos, Evangelos

Published
2021
Full Text
View/download PDF

22. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Author

Mateos, Maria Victoria, primary, Weisel, Katja, additional, Terpos, Evangelos, additional, Delimpasi, Sossana, additional, Kastritis, Efstathios, additional, Zamagni, Elena, additional, Delforge, Michel, additional, Ocio, Enrique, additional, Katodritou, Eirini, additional, Gay, Francesca, additional, Larocca, Alessandra, additional, Leleu, Xavier, additional, Otero, Paula Rodriguez, additional, Schjesvold, Fredik, additional, Cavo, Michele, additional, and Dimopoulos, Meletios A., additional

Published
2024
Full Text
View/download PDF

23. The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Author

Hillengass, Jens, primary, Cohen, Adam D., additional, Agha, Mounzer, additional, Delforge, Michel, additional, Kerre, Tessa, additional, Roeloffzen, Wilfried, additional, Einsele, Hermann, additional, Goldschmidt, Hartmut, additional, Weisel, Katja, additional, Raab, Marc-Steffen, additional, Scheid, Christoph, additional, Anguille, Sébastien, additional, Sonneveld, Pieter, additional, Zweegman, Sonja, additional, Schecter, Jordan M, additional, De Braganca, Kevin C., additional, Jackson, Carolyn C, additional, Vlummens, Philip, additional, Varsos, Helen, additional, Corsale, Christina, additional, Madduri, Deepu, additional, Yeh, Tzu-min, additional, Mistry, Pankaj, additional, Roccia, Tito, additional, Song, Qingxuan, additional, Akram, Muhammad, additional, Filho, Octavio Costa, additional, Geng, Dong, additional, Cohen, Yael C, additional, and van de Donk, Niels W.C.J., additional

Published
2024
Full Text
View/download PDF

24. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits in the native or posttransplant kidney

Author

Verbinnen, Margo, primary, Sprangers, Ben, additional, Abrahams, Alferso C, additional, Koshy, Priyanka, additional, Van Kruijsdijk, Rob C M, additional, Philipse, Ester, additional, Michalak, Magdalena, additional, Delforge, Michel, additional, Vos, Josephine M I, additional, Wetzels, Jack, additional, Dendooven, Amélie, additional, and Van Craenenbroeck, Amaryllis H, additional

Published
2024
Full Text
View/download PDF

25. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Author

Moreau, Philippe, Hulin, Cyrille, Perrot, Aurore, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Béné, Marie C, Zweegman, Sonja, Caillon, Hélène, Caillot, Denis, Corre, Jill, Delforge, Michel, Dejoie, Thomas, Doyen, Chantal, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Mohty, Mohamad, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Orsini-Piocelle, Frédérique, Roussel, Murielle, Stoppa, Anne-Marie, van de Donk, Niels W C J, Wuillème, Soraya, Broijl, Annemiek, Touzeau, Cyrille, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Offner, Fritz, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Réda, Ahmadi, Tahamtan, Krevvata, Maria, Zhang, Ke, de Boer, Carla, Vara, Sanjay, Kampfenkel, Tobias, Vanquickelberghe, Veronique, Vermeulen, Jessica, Avet-Loiseau, Hervé, and Sonneveld, Pieter

Published
2021
Full Text
View/download PDF

29. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, Heinz, Boccadoro, Mario, Moreau, Philippe, San-Miguel, Jesus, Cavo, Michele, Pawlyn, Charlotte, Zweegman, Sonja, Facon, Thierry, Driessen, Christoph, Hajek, Roman, Dimopoulos, Melitios A., Gay, Francesca, Avet-Loiseau, Hervé, Terpos, Evangelos, Zojer, Niklas, Mohty, Mohamad, Mateos, Maria-Victoria, Einsele, Hermann, Delforge, Michel, Caers, Jo, Weisel, Katja, Jackson, Graham, Garderet, Laurent, Engelhardt, Monika, van de Donk, Niels, Leleu, Xavier, Goldschmidt, Hartmut, Beksac, Meral, Nijhof, Inger, Abildgaard, Niels, Bringhen, Sara, and Sonneveld, Pieter

Published
2021
Full Text
View/download PDF

30. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT

Author

Gagelmann, Nico, Eikema, Diderik-Jan, de Wreede, Liesbeth C., Rambaldi, Alessandro, Iacobelli, Simona, Koster, Linda, Caillot, Denis, Blaise, Didier, Remémyi, Péter, Bulabois, Claude-Eric, Passweg, Jakob, Leleu, Xavier, Zver, Samo, Kobbe, Guido, Ljungman, Per, Chevallier, Patrice, Ringhoffer, Mark, Martin, Murray, Salmenniemi, Urpu, Poiré, Xavier, Lenhoff, Stig, Pioltelli, Pietro, Mordini, Nicola, Delforge, Michel, Garderet, Laurent, Schönland, Stefan, Yakoub-Agha, Ibrahim, and Kröger, Nicolaus

Published
2021
Full Text
View/download PDF

31. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Author

Sonneveld, Pieter, primary, Dimopoulos, Meletios A., additional, Boccadoro, Mario, additional, Quach, Hang, additional, Ho, P. Joy, additional, Beksac, Meral, additional, Hulin, Cyrille, additional, Antonioli, Elisabetta, additional, Leleu, Xavier, additional, Mangiacavalli, Silvia, additional, Perrot, Aurore, additional, Cavo, Michele, additional, Belotti, Angelo, additional, Broijl, Annemiek, additional, Gay, Francesca, additional, Mina, Roberto, additional, Nijhof, Inger S., additional, van de Donk, Niels W.C.J., additional, Katodritou, Eirini, additional, Schjesvold, Fredrik, additional, Sureda Balari, Anna, additional, Rosiñol, Laura, additional, Delforge, Michel, additional, Roeloffzen, Wilfried, additional, Silzle, Tobias, additional, Vangsted, Annette, additional, Einsele, Hermann, additional, Spencer, Andrew, additional, Hajek, Roman, additional, Jurczyszyn, Artur, additional, Lonergan, Sarah, additional, Ahmadi, Tahamtan, additional, Liu, Yanfang, additional, Wang, Jianping, additional, Vieyra, Diego, additional, van Brummelen, Emilie M.J., additional, Vanquickelberghe, Veronique, additional, Sitthi-Amorn, Anna, additional, de Boer, Carla J., additional, Carson, Robin, additional, Rodriguez-Otero, Paula, additional, Bladé, Joan, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

32. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Author

Sonneveld, Pieter, primary, Dimopoulos, Meletios A., additional, Boccadoro, Mario, additional, Quach, Hang, additional, Ho, P. Joy, additional, Beksac, Meral, additional, Hulin, Cyrille, additional, Antonioli, Elisabetta, additional, Leleu, Xavier, additional, Mangiacavalli, Silvia, additional, Perrot, Aurore, additional, Cavo, Michele, additional, Belotti, Angelo, additional, Broijl, Annemiek, additional, Gay, Francesca, additional, Mina, Roberto, additional, Nijhof, Inger S., additional, van de Donk, Niels W.C.J, additional, Katodritou, Eirini, additional, Schjesvold, Fredrik, additional, Sureda Balari, Anna, additional, Rosiñol, Laura, additional, Delforge, Michel, additional, Roeloffzen, Wilfried, additional, Silzle, Tobias, additional, Vangsted, Annette, additional, Einsele, Hermann, additional, Spencer, Andrew, additional, Hajek, Roman, additional, Jurczyszyn, Artur, additional, Lonergan, Sarah, additional, Ahmadi, Tahamtan, additional, Liu, Yanfang, additional, Wang, Jianping, additional, Vieyra, Diego, additional, van Brummelen, Emilie M.J., additional, Vanquickelberghe, Veronique, additional, Sitthi-Amorn, Anna, additional, de Boer, Carla J., additional, Carson, Robin, additional, Rodríguez Otero, Paula, additional, Bladé, Joan, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

33. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Author

Tremblay, Gabriel, Daniele, Patrick, Breeze, Janis, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Engelhardt, Monika, Chari, Ajaj, Nooka, Ajay, Vogl, Dan, Gavriatopoulou, Maria, Dimopoulos, Meletios-Athanasios, Richardson, Paul, Biran, Noa, Siegel, David, Vlummens, Philip, Doyen, Chantal, Facon, Thierry, Mohty, Mohamad, Meuleman, Nathalie, Levy, Moshe, Costa, Luciano, Hoffman, James E., Delforge, Michel, Kaminetzky, David, Weisel, Katja, Raab, Marc, Dingli, David, Tuchman, Sascha, Laurent, Frenzel, Vij, Ravi, Schiller, Gary, Moreau, Philippe, Richter, Joshua, Schreder, Martin, Podar, Klaus, Parker, Terri, Cornell, Robert Frank, Lionel, Karlin, Choquet, Sylvain, and Sundar, Jagannath

Published
2021
Full Text
View/download PDF

35. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)

Author

Hillengass, Jens, Cohen, Adam D, Delforge, Michel, Einsele, Hermann, Goldschmidt, Hartmut, Weisel, Katja, Raab, Marc-Steffen, Scheid, Christof, Schecter, Jordan M, de Braganca, Kevin C, Varsos, Helen, Yeh, Tzu-min, Mistry, Pankaj, Roccia, Tito, Corsale, Christina, Akram, Muhammad, Pacaud, Lida, Nesheiwat, Tonia, Agha, Mounzer, and Cohen, Yael C

Published
2022
Full Text
View/download PDF

36. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

Author

van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C, Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A, Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K, Delforge, Michel, Levin, Mark-David, Bos, Gerard M, Jie, Kon-Siong G, Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G, Zweegman, Sonja, Sonneveld, Pieter, and Lokhorst, Henk M

Published
2018
Full Text
View/download PDF

37. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

Author

Moreau, Philippe, Mateos, María-Victoria, Gonzalez Garcia, Maria Esther, Einsele, Hermann, De Stefano, Valerio, Karlin, Lionel, Lindsey-Hill, Joanne, Besemer, Britta, Vincent, Laure, Kirkpatrick, Suriya, Delforge, Michel, Perrot, Aurore, van de Donk, Niels W. C. J., Pawlyn, Charlotte, Manier, Salomon, Leleu, Xavier, Martinez-Lopez, Joaquin, Ghilotti, Francesca, Diels, Joris, and Morano, Raúl

Abstract

Introduction: Teclistamab is the first approved B cell maturation antigen × CD3 bispecific antibody with precision dosing for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). We compared the effectiveness of teclistamab in MajesTEC-1 versus real-world physician's choice of therapy (RWPC) in patients from the prospective, non-interventional LocoMMotion and MoMMent studies. Methods: Patients treated with teclistamab from MajesTEC-1 (N = 165) were compared with an external control arm from LocoMMotion (N = 248) or LocoMMotion + MoMMent pooled (N = 302). Inverse probability of treatment weighting adjusted for imbalances in prognostic baseline characteristics. The relative effect of teclistamab versus RWPC for overall response rate (ORR), very good partial response or better (≥ VGPR) rate, and complete response or better (≥ CR) rate was estimated with an odds ratio using weighted logistic regression transformed into a response-rate ratio (RR) and 95% confidence interval (CI). Weighted proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs for duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Results: Baseline characteristics were well balanced between treatment cohorts after reweighting. Patients treated with teclistamab had significantly improved outcomes versus RWPC in LocoMMotion: ORR (RR [95% CI], 2.44 [1.79–3.33]; p < 0.0001), ≥ VGPR (RR 5.78 [3.74–8.93]; p < 0.0001), ≥ CR (RR 113.73 [15.68–825.13]; p < 0.0001), DOR (HR 0.39 [0.24–0.64]; p = 0.0002), PFS (HR 0.48 [0.35–0.64]; p < 0.0001), and OS (HR 0.64 [0.46–0.88]; p = 0.0055). Teclistamab versus RWPC in LocoMMotion + MoMMent also had significantly improved outcomes: ORR (RR 2.41 [1.80–3.23]; p < 0.0001), ≥ VGPR (RR 5.91 [3.93–8.88]; p < 0.0001), ≥ CR (RR 132.32 [19.06–918.47]; p < 0.0001), DOR (HR 0.43 [0.26–0.71]; p = 0.0011), PFS (HR 0.49 [0.37–0.66]; p < 0.0001), and OS (HR 0.69 [0.50–0.95]; p = 0.0247). Conclusion: Teclistamab demonstrated significantly improved effectiveness over RWPC in LocoMMotion ± MoMMent, emphasizing its clinical benefit as a highly effective treatment for patients with TCE RRMM. Trial Registration: MajesTEC-1, ClinicalTrials.gov NCT03145181 (phase 1) and NCT04557098 (phase 2); LocoMMotion, ClinicalTrials.gov NCT04035226; MoMMent, ClinicalTrials.gov NCT05160584. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. POSTER: MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-Up

Author

Moreau, Philippe, primary, Weisel, Katja, additional, de Stefano, Valerio, additional, Goldschmidt, Hartmut, additional, Delforge, Michel, additional, Mohty, Mohamad, additional, Lindsey-Hill, Joanne, additional, Dytfeld, Dominik, additional, Angelucci, Emanuele, additional, Vincent, Laure, additional, Perrot, Aurore, additional, Benjamin, Reuben, additional, van de Donk, Niels, additional, Ocio, Enrique, additional, in ’t Groen-Damen, Ester, additional, Roccia, Tito, additional, Schecter, Jordan, additional, Haddad, Imène, additional, Strulev, Vadim, additional, Mitchell, Lada, additional, Buyze, Jozefien, additional, Saarinen, Silva, additional, Costa, Octavio, additional, Einsele, Hermann, additional, and Mateos, María-Victoria, additional

Published
2023
Full Text
View/download PDF

39. POSTER: CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)

Author

Giralt, Sergio, primary, Ailawadhi, Sikander, additional, Arnulf, Bertrand, additional, Patel, Krina, additional, Cavo, Michele, additional, Nooka, Ajay K., additional, Manier, Salomon, additional, Callander, Natalie, additional, Costa, Luciano J., additional, Vij, Ravi, additional, Bahlis, Nizar J., additional, Moreau, Philippe, additional, Solomon, Scott R., additional, Delforge, Michel, additional, Berdeja, Jesús, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Favre-Kontula, Linda, additional, Wu, Fan, additional, Piasecki, Julia, additional, Cook, Mark, additional, and Rodríguez-Otero, Paula, additional

Published
2023
Full Text
View/download PDF

40. POSTER: MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update

Author

Hultcrantz, Malin, primary, Kleinman, David, additional, Vij, Ravi, additional, Escalante, Fernando, additional, Delforge, Michel, additional, Kotowsky, Nirali, additional, Bitetti, Jacopo, additional, Boytsov, Natalie, additional, Camadoo-O'Byrne, Leena, additional, Happ, Lindsey Powers, additional, Rohman, Mujib, additional, Germain, Guillaume, additional, Duh, Mei Sheng, additional, Laliberté, François, additional, Mahendran, Malena, additional, Urosevic, Ana, additional, and Lee, Hans, additional

Published
2023
Full Text
View/download PDF

41. P-008 Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy

Author

Einsele, Hermann, primary, Rodriguez-Otero, Paula, additional, Arnulf, Bertrand, additional, Patel, Krina, additional, Manier, Salomon, additional, Costa, Luciano, additional, Bahlis, Nizar, additional, Broijl, Annemiek, additional, Chen, Christine, additional, Abrahamsen, Ingerid Weum, additional, Delforge, Michel, additional, Gergis, Usama, additional, Raab, Marc, additional, Singhal, Seema, additional, Abonour, Rafat, additional, Truppel-Hartmann, Anna, additional, Bhatnagar, Rashmi, additional, Felten, Jasper, additional, Caia, Andrea, additional, Wu, Fan, additional, Piasecki, Julia, additional, Cook, Mark, additional, and Ailawadhi, Sikander, additional

Published
2023
Full Text
View/download PDF

42. P-040 Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis

Author

Patel, Krina, primary, Rodriguez-Otero, Paula, additional, Manier, Salomon, additional, Baz, Rachid, additional, Raab, Marc, additional, Cavo, Michele, additional, Callander, Natalie, additional, Costa, Luciano, additional, Moreau, Philippe, additional, Solomon, Scott, additional, Chen, Christine, additional, Raje, Noopur, additional, Scheid, Christoph, additional, Delforge, Michel, additional, Larsen, Jeremy, additional, Pabst, Thomas Mueller, additional, Suzuki, Kenshi, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, Giralt, Sergio, additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

43. POSTER: MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups

Author

Patel, Krina, primary, Rodríguez-Otero, Paula, additional, Manier, Salomon, additional, Baz, Rachid, additional, Raab, Mark-Steffen, additional, Cavo, Michele, additional, Callander, Natalie, additional, Costa, Luciano J., additional, Moreau, Phillippe, additional, Solomon, Scott, additional, Chen, Christine, additional, Raje, Noopur, additional, Scheid, Christoph, additional, Delforge, Michel, additional, Larsen, Jeremy, additional, Pabst, Thomas, additional, Suzuki, Kenshi, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, Giralt, Sergio, additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

44. P-325 Standard of care (SOC) outcomes in the last 3 years in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): the first pooled analysis of LocoMMotion and MoMMent trials

Author

Weisel, Katja, primary, Mateos, Maria-Victoria, additional, Garcia, Maria Esther Gonzalez, additional, Bittrich, Max, additional, Lindsey-Hill, Joanne, additional, De Stefano, Valerio, additional, Besemer, Britta, additional, Vincent, Laure, additional, Kirkpatrick, Suriya, additional, Karlin, Lionel, additional, Goldschmidt, Hartmut, additional, Conticello, Concetta, additional, Roeloffzen, Wilfried, additional, van de Donk, Niels, additional, Delforge, Michel, additional, Doyle, Margaret, additional, Gray, Kathleen, additional, Albrecht, Claire, additional, Strulev, Vadim, additional, Haddad, Imène, additional, Saarinen, Silva, additional, Mitchell, Lada, additional, Buyze, Jozefien, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

45. P-324 LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up

Author

Weisel, Katja, primary, Moreau, Philippe, additional, De Stefano, Valerio, additional, Goldschmidt, Hartmut, additional, Delforge, Michel, additional, Mohty, Mohamad, additional, Lindsey-Hill, Joanne, additional, Dytfeld, Dominik, additional, Angelucci, Emanuele, additional, Vincent, Laure, additional, Perrot, Aurore, additional, Benjamin, Reuben, additional, van de Donk, Niels, additional, Ocio, Enrique, additional, Groen-Damen, Ester in't, additional, Roccia, Tito, additional, Schecter, Jordan, additional, Haddad, Imène, additional, Strulev, Vadim, additional, Mitchell, Lada, additional, Buyze, Jozefien, additional, Saarinen, Silva, additional, Filho, Octavio Costa, additional, Einsele, Hermann, additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

46. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

Author

Avivi, Irit, primary, Vesole, David H., additional, Davila-Valls, Julio, additional, Usnarska-Zubkiewicz, Lidia, additional, Olszewska-Szopa, Magdalena, additional, Milunovic, Vibor, additional, Baumert, Bartłomiej, additional, Osękowska, Bogumiła, additional, Kopińska, Anna, additional, Gentile, Massimo, additional, Puertas-Martinez, Borja, additional, Robak, Paweł, additional, Crusoe, Edvan, additional, Rodriguez-Lobato, Luis Gerardo, additional, Gajewska, Małgorzata, additional, Varga, Gergely, additional, Delforge, Michel, additional, Cohen, Yael, additional, Gozzetti, Alessandro, additional, Pena, Camila, additional, Shustik, Chaim, additional, Mikala, Gabor, additional, Zalac, Klara, additional, Alexander, H. Denis, additional, Barth, Peter, additional, Weisel, Katja, additional, Martínez-López, Joaquín, additional, Waszczuk-Gajda, Anna, additional, Krzystański, Mateusz, additional, and Jurczyszyn, Artur, additional

Published
2023
Full Text
View/download PDF

47. MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

van de Donk, Niels, primary, Moreau, Philippe, additional, Garfall, Alfred, additional, Bhutani, Manisha, additional, Oriol, Albert, additional, Nooka, Ajay, additional, Martin, Thomas, additional, Rosinol, Laura, additional, Mateos, Maria-Victoria, additional, Bahlis, Nizar, additional, Popat, Rakesh, additional, Besemer, Britta, additional, Lopez, Joaquin Martinez, additional, Krishnan, Amrita, additional, Delforge, Michel, additional, Trancucci, Danielle, additional, Verona, Raluca, additional, Stephenson, Tara, additional, Chastain, Katherine, additional, and Sidana, Surbhi, additional

Published
2023
Full Text
View/download PDF

48. MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update

Author

Hultcrantz, Malin, primary, Kleinman, David, additional, Vij, Ravi, additional, Escalante, Fernando, additional, Delforge, Michel, additional, Kotowsky, Nirali, additional, Bitetti, Jacopo, additional, Boytsov, Natalie, additional, Camadoo-O'Byrne, Leena, additional, Happ, Lindsey Powers, additional, Rohman, Mujib, additional, Germain, Guillaume, additional, Duh, Mei Sheng, additional, Laliberté, François, additional, Mahendran, Malena, additional, Urosevic, Ana, additional, and Lee, Hans, additional

Published
2023
Full Text
View/download PDF

50. CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)

Author

Giralt, Sergio, primary, Ailawadhi, Sikander, additional, Arnulf, Bertrand, additional, Patel, Krina, additional, Cavo, Michele, additional, Nooka, Ajay K., additional, Manier, Salomon, additional, Callander, Natalie, additional, Costa, Luciano J., additional, Vij, Ravi, additional, Bahlis, Nizar J., additional, Moreau, Philippe, additional, Solomon, Scott R., additional, Delforge, Michel, additional, Berdeja, Jesús, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Favre-Kontula, Linda, additional, Wu, Fan, additional, Piasecki, Julia, additional, Cook, Mark, additional, and Rodríguez-Otero, Paula, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results